An international cancer research consortium is setting out to map and drug the “dark proteome” — non-canonical proteins largely hidden from conventional genomic approaches that could provide a new source of tumor-specific targets for immunotherapies and small molecules. The NCI-backed ILLUMINE program is led scientifically by Reuven Agami at the Netherlands Cancer Institute, with Dana-Farber Cancer Institute's Catherine Wu heading the US award.
The dark proteome encompasses non-canonical proteins and peptides generated outside conventionally annotated protein-coding open reading frames, potentially through mechanisms including alternative translation and dysregulated RNA processing. Because standard genomic pipelines are generally built around known genes and mutations, many of these products may escape conventional cancer target discovery.
The USD 1.16 million OT2 award supports Dana-Farber as the US administrative home of the program. ILLUMINE will catalogue dark proteome entities across major cancer types, build a preclinical immunotherapy development pipeline around them, characterize their functions in cancer biology, and explore non-immunotherapy targeting opportunities including small molecules.
The translational rationale centers on the possibility that dark proteome-derived peptides presented by major histocompatibility complex (MHC) molecules on cancer cells could serve as tumor-specific antigens for T-cell-based therapies. Such peptides could provide tumor antigens that conventional neoantigen discovery pipelines miss because their source proteins are not encoded by annotated protein-coding sequences or explained by tumor DNA mutations. The program also intends to explore whether dark proteins directly modulate oncogenic signaling, potentially opening drug discovery avenues beyond immunotherapy.